An Italian oncologic psychologist warns these patients: “A prostatectomy doesn’t cure anxiety.” Emotional distress can be so ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...

You can’t change your age, ethnicity or family history, but you can take control of your lifestyle.

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Risk factors like Gleason score, cancer stage, PSA levels, and genetic markers guide prostate cancer treatment decisions. Treatment options include active surveillance, surgery, radiation, hormone ...

March 28, 2011 (Vienna, Austria) — Phase 2 study results of padeliporfin (Tookad, Steba Biotech) in patients with low-risk prostate cancer yielded negative biopsies in more than 80% of patients ...

Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...